187 filings
Page 3 of 10
8-K
vi1plykdw2zcvm5
9 Dec 21
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
8:01am
8-K
aagdp 71g9asehp
15 Nov 21
Departure of Directors or Certain Officers
7:01am
8-K
alm4fft kk
10 Nov 21
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
4:29pm
8-K
boc sy7k0f00wd05o5
19 Aug 21
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
4:12pm
8-K
t3nnlq6uync2ucsg6b
10 Aug 21
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
4:08pm
8-K
1yi9ei5pu
28 Jul 21
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
4:36pm
8-K
34zei5
6 Jul 21
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML
7:23am
8-K
m7tql4b rm
11 Jun 21
Submission of Matters to a Vote of Security Holders
8:00am
8-K
bmdmupbh4afnqx6nuk
12 May 21
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:17pm
8-K
a0jsxilzuwy vpf
16 Mar 21
CORPORATE PRESENTATION March 2021
5:16pm
8-K
wvywtcdj9i
9 Mar 21
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
4:36pm
8-K
tmm3f7t g6hjbrinil5
3 Mar 21
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
7:41am
8-K
rxaubwaxs822geac
13 Jan 21
Regulation FD Disclosure
7:43am
8-K
b8tuwtygosxf emr3r
5 Jan 21
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
4:01pm
8-K
q93 ut4qm
9 Nov 20
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:18pm
8-K
sym yziu3ea2vhsot
10 Aug 20
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
4:29pm
8-K
z6wy3pos5qmvrxns
30 Jun 20
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
9:13am
8-K
94ba0k
23 Jun 20
Regulation FD Disclosure
8:51am
8-K
rsikk6t8 m1wrpm
1 Jun 20
Regulation FD Disclosure
9:22am
8-K
mkunp8hursozwmt
29 May 20
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical
8:17am